A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK3640254 in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs GSK 3640254 (Primary)
- Indications HIV infections
- Focus Adverse reactions; First in man
- Sponsors ViiV Healthcare
- 13 Sep 2018 Status changed from recruiting to completed.
- 27 Aug 2018 Planned End Date changed from 27 Aug 2018 to 5 Sep 2018.
- 27 Aug 2018 Planned primary completion date changed from 27 Aug 2018 to 5 Sep 2018.